BeOne Medicines Ltd. (ONC) operating KPIs
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$370.33−1.23 (-0.33%)
Close on Oct 30, 2026Market cap $42.11BP/E 66.2Yield –
BeOne Medicines provision for Sales Rebates & Returns Charged to Revenue ($M) ($M)
Form 10-Q / 10-K Accrued Sales Rebates Rollforward Note (XBRL)
Latest, Q2 2026
526
Period ended Jun 30, 2026
Change on a year earlier
+47.8%
356 in Q2 2025
History
36 quarters
Since Q3 2017
Sources
29
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Provision for Sales Rebates & Returns Charged to Revenue ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 526 | +47.8% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2026 | Mar 31, 2026 | 406 | +39.3% | Form 10-Q (filed 2026-05-06) ↗ |
| Q4 2025 | Dec 31, 2025 | 426 | +36.7% | Form 10-K (filed 2026-02-26) ↗ |
| Q3 2025 | Sep 30, 2025 | 376 | +49.0% | Form 10-Q (filed 2025-11-06) ↗ |
| Q2 2025 | Jun 30, 2025 | 356 | +44.6% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2025 | Mar 31, 2025 | 292 | +47.5% | Form 10-Q (filed 2026-05-06) ↗ |
| Q4 2024 | Dec 31, 2024 | 312 | +73.1% | Form 10-K (filed 2026-02-26) ↗ |
| Q3 2024 | Sep 30, 2024 | 252 | +85.1% | Form 10-Q (filed 2025-11-06) ↗ |
| Q2 2024 | Jun 30, 2024 | 246 | +15.5% | Form 10-Q (filed 2025-08-06) ↗ |
| Q1 2024 | Mar 31, 2024 | 198 | +99.0% | Form 10-Q (filed 2025-05-07) ↗ |
| Q4 2023 | Dec 31, 2023 | 180 | +186.6% | Form 10-K (filed 2026-02-26) ↗ |
| Q3 2023 | Sep 30, 2023 | 136 | +178.5% | Form 10-Q (filed 2024-11-12) ↗ |
| Q2 2023 | Jun 30, 2023 | 213 | +194.9% | Form 10-Q (filed 2023-08-02) ↗ |
| Q1 2023 | Mar 31, 2023 | 99.3 | +193.8% | Form 10-Q (filed 2024-05-08) ↗ |
| Q4 2022 | Dec 31, 2022 | 62.8 | +15.9% | Form 10-K (filed 2025-02-27) ↗ |
| Q3 2022 | Sep 30, 2022 | 48.9 | +259.6% | Form 10-Q (filed 2023-11-09) ↗ |
| Q2 2022 | Jun 30, 2022 | 72.2 | +644.3% | Form 10-Q (filed 2023-08-02) ↗ |
| Q1 2022 | Mar 31, 2022 | 33.8 | -9.6% | Form 10-Q (filed 2023-05-04) ↗ |
| Q4 2021 | Dec 31, 2021 | 54.2 | +545.2% | Form 10-K (filed 2023-02-27) ↗ |
| Q3 2021 | Sep 30, 2021 | 13.6 | +216.3% | Form 10-Q (filed 2022-11-09) ↗ |
| Q2 2021 | Jun 30, 2021 | 9.70 | +385.0% | Form 10-Q (filed 2022-08-08) ↗ |
| Q1 2021 | Mar 31, 2021 | 37.4 | +3,300.0% | Form 10-Q (filed 2022-05-09) ↗ |
| Q4 2020 | Dec 31, 2020 | 8.40 | +300.0% | Form 10-K (filed 2022-02-28) ↗ |
| Q3 2020 | Sep 30, 2020 | 4.30 | +87.0% | Form 10-Q (filed 2021-11-04) ↗ |
| Q2 2020 | Jun 30, 2020 | 2 | +233.3% | Form 10-Q (filed 2021-08-05) ↗ |
| Q1 2020 | Mar 31, 2020 | 1.10 | 0.0% | Form 10-Q (filed 2021-05-06) ↗ |
| Q4 2019 | Dec 31, 2019 | 2.10 | -36.4% | Form 10-K (filed 2021-02-25) ↗ |
| Q3 2019 | Sep 30, 2019 | 2.30 | -32.4% | Form 10-Q (filed 2020-11-05) ↗ |
| Q2 2019 | Jun 30, 2019 | 0.60 | +200.0% | Form 10-Q (filed 2020-08-06) ↗ |
| Q1 2019 | Mar 31, 2019 | 1.10 | +450.0% | Form 10-Q (filed 2019-05-09) ↗ |
| Q4 2018 | Dec 31, 2018 | 3.30 | +43.5% | Form 10-K (filed 2020-03-02) ↗ |
| Q3 2018 | Sep 30, 2018 | 3.40 | +100.0% | Form 10-Q (filed 2018-11-08) ↗ |
| Q2 2018 | Jun 30, 2018 | 0.20 | – | Form 10-Q (filed 2018-08-09) ↗ |
| Q1 2018 | Mar 31, 2018 | 0.20 | – | Form 10-Q (filed 2018-05-09) ↗ |
| Q4 2017 | Dec 31, 2017 | 2.30 | – | Form 10-K (filed 2019-02-28) ↗ |
| Q3 2017 | Sep 30, 2017 | 1.70 | – | Form 10-Q (filed 2018-11-08) ↗ |
Cite this data
StockData. (2026). BeOne Medicines Provision for Sales Rebates & Returns Charged to Revenue ($M) ($M), quarterly Q3 2017–Q2 2026 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/gtn_provision
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.